

SYNTHESIS OF CERATINAMINE AND MOLOKA'IAMINE: ANTIFOULING AGENTS FROM THE MARINE SPONGE *Pseudoceratina purpurea*

Ryan C. Schoenfeld and Bruce Ganem*

*Department of Chemistry, Baker Laboratory
Cornell University, Ithaca, NY 14853-1301 USA*


Received 23 February 1998; accepted 3 April 1998

Abstract: Syntheses of the title compounds (**4** and **5**, respectively) are described together with a biogenetic hypothesis that rationalizes the origin of ceratinamine's unique cyanoforamide functionality.


© 1998 Elsevier Science Ltd. All rights reserved.

Tin-containing antifouling paints, which prevent the growth of marine organisms on ships' hulls that increases hydrodynamic drag, are associated with several significant environmental problems, including acute toxicity in marine mammals, long-term reproductive effects, and increased shell thickness in crustaceans.^{1,2} Since 1987, a ban on tin-containing paints has been enforced in Europe, North America, and Australasia, prompting the quest for safe and effective alternatives.

Several laboratories have searched for natural antifouling agents in marine organisms, where potent chemical defense systems keep the larvae of predators from settling and attaching to their prey. Many of the active antifouling compounds identified to date are bromotyrosine derivatives, including psammaphysin A **1** from the verongid sponge *Psammaphysilla purpurea*.³ Together with **1**, ceratinamide A **2**, ceratinamide B **3**, ceratinamine **4** and moloka'iamine **5** have been isolated from the sponge *Pseudoceratina purpurea* collected near Japan.^{4,5} Here we report practical and efficient total syntheses of ceratinamine, the first example of a cyanoforamide-containing natural product, as well as moloka'iamine. The cyanoforamide in **4** is seen to arise as part of a unified scheme for the biogenesis of **1-5** from a common bromotyrosine-derived precursor.




Retrosynthetic analysis suggested that both **4** and **5** might be accessible from a congener of **5** having an appropriately protected aminoethyl group. Planning a deprotection strategy, however, was limited by the scant literature on ceratinamine, and on cyanoamides in general.^{6,7} Fortunately, the isolation of **4** involved a successful HPLC purification using CH₃CN-H₂O containing 0.01% trifluoroacetic acid (TFA), conditions under which rapid cleavage of the acid-labile 2-(4-biphenyl)-prop-2-ylloxycarbonyl (Bpoc) protecting group⁸ was expected to occur. Condensation of dibromotyramine **6** (Scheme 1)⁹ with Bpoc-OC₆H₄(p-CO₂CH₃) (Fluka) using Triton B catalyst¹⁰ afforded **7**, which was subsequently aminopropylated to give aminoether **9** in high yield after deprotection. Direct deprotection of **8** afforded moloka'iamine **5**•2 HCl (mp >300 °C) whose ¹H-NMR spectrum was identical with that of a naturally derived sample. Acylation of **9** with carbonyl cyanide, prepared using a slight modification⁷ of the *Organic Syntheses* procedure,¹¹ furnished **10** (92%). Removal of the Bpoc group with dilute acid gave ceratinamine **4**•TFA (90%, mp 133-4 °C), which was spectroscopically identical with an authentic sample. Overall, the synthesis produced **4** in 5 steps and 52% yield from dibromotyramine.




Scheme 1

The TFA salt of **4** was stable in CD₃OD at rt, but underwent slow hydrolysis in D₂O ($t_{1/2}$ = 31 days at 24 °C, pD 5.5). In 1% KOH-CH₃OH, **4** was rapidly converted to the known¹² carbamate **11** with release of cyanide (positive benzidine test).

The biogenesis of **1-5**, as well as other bromotyrosine metabolites, has elicited widespread interest.^{3,13} No reports have addressed the origin of ceratinamine's unique cyanoforamide group, although in retrospect, an important clue surfaced during the isolation of psammaplysin A. In that work, Rotem *et al.* noted¹² that treatment of **1** with methanolic base gave carbamate **11** along with an aryl aldehyde that was subsequently identified⁵ as **12**.



In Scheme 2, we propose a mechanism for the base-catalyzed rupture of the spiro[4,6]-dioxazaundecane framework to form ceratinamine **4**, which we have now shown is converted to **11** under the reaction conditions. The other primary fragmentation product, hydroxyaldehyde **13**, would subsequently be transformed into **12** as shown. Similar isoxazole-to-nitrile fragmentations have been observed under physiological conditions with 3-unsubstituted isoxazoles, 3-acylisoxazoles, and isoxazole-3-carboxylic acids.^{14,15}



Scheme 2

Interestingly, cyanide can be detected when sponges of the genus *Psammaplysilla* and *Pseudoceratina* are broken into pieces.³ The mechanism proposed in Scheme 2 along with experimental data on the stability of ceratinamine rationalize this observation, since further hydrolysis of the cyanoforamide in **4** to moloka'iamine **5** would result in the release of HCN.

ACKNOWLEDGMENT: We thank Drs. Nobuhiro Fusetani and Sachiko Tsukamoto for providing IR and NMR spectra of authentic ceratinamine, and Drs. Paul Scheuer and Mark Hamann for the ¹H-NMR spectrum of moloka'iamine. Generous financial support of the Cornell NMR Facility has been provided by the NSF (CHE 7904825; PGM 8018643) and NIH (RR02002).

REFERENCES AND NOTES

1. Iwata, H.; Tanabe, S.; Mizuno, T.; Tatsukawa, R. *Environ. Sci. Tech.* **1995**, *29*, 2959.
2. Ohhira, S.; Matsui, H.; Nitta, K. *Vet. Human Toxicol.* **1996**, *38*, 206.
3. Roll, D. M.; Chang, C. W. J.; Scheuer, P. J.; Gray, G. A.; Shoolery, J. N.; Matsumoto, G. K.; Van Duyne, G. D.; Clardy, J. *J. Am. Chem. Soc.* **1985**, *107*, 2916.
4. Tsukamoto, S.; Kato, H.; Hiroka, H.; Fusetani, N. *J. Org. Chem.* **1996**, *61*, 2936.
5. Hamann, M. T.; Scheuer, P. J.; Kelly-Borges, M. *J. Org. Chem.* **1993**, *58*, 6565.
6. Malachowski, R.; Jankiewicz-Wasowska, J. *Roczniki Chem.* **1951**, *25*, 35; *Chem. Abstr.* **1953**, *47*, 10483f.
7. Ford, R. E.; Knowles, P.; Lunt, E.; Marshall, S. M.; Penrose, A. J.; Ramsden, C. A.; Summers, A. J. H.; Walker, J. L.; Wright, D. E. *J. Med. Chem.* **1986**, *29*, 538.
8. (a) Sieber, P.; Iselin, B. *Helv. Chim. Acta* **1968**, *51*, 614, 622; (b) Schnabel, E.; Schmidt, G.; Klauke, E. *Liebigs Ann. Chem.* **1971**, *743*, 69.
9. (a) Zeynek, R. *Z. Physiol. Chem.* **1921**, *114*, 275; (b) Benington, F.; Morin, R. D.; Clark, Jr., L. C.; Fox, R. P. *J. Org. Chem.* **1958**, *23*, 1979.
10. Kemp, D. S.; Fotouhi, N.; Boyd, J. G.; Carey, R. I.; Ashton, C.; Hoare, J. *Int. J. Peptide Protein Res.* **1986**, *31*, 359.
11. (a) Martin, E. L. *Org. Syn.* **1971**, *51*, 70; (b) Martin, E. L. *Org. Syn. Coll. Vol. 6* **1987**, 268.
12. Rotem, M.; Carmely, S.; Kashman, Y.; Loya, Y. *Tetrahedron* **1983**, *39*, 667.
13. (a) De Rosa, M.; Minale, L.; Sodano, G. *Comp. Biochem. Physiol.* **1973**, *i45B*, 883; (b) Tymiak, A. A.; Rinehart, Jr., K. L. *J. Am. Chem. Soc.* **1981**, *103*, 6763; (c) Carney, J. R.; Rinehart, K. L. *J. Nat. Prod.* **1995**, *7*, 971.
14. Grunanger, P.; Vita-Finzi, P. "Isoxazoles, Part One," in *The Chemistry of Heterocyclic Compounds*, Taylor, E. C.; Weissberger, A.; Eds.; Wiley, New York, **1991**, p. 298.
15. (a) Shah, S. C.; Smid, J. *J. Am. Chem. Soc.* **1978**, *100*, 1426; (b) Bunton, C. A.; Minch, M. J.; Hidalgo, J.; Sepulveda, L. *J. Am. Chem. Soc.* **1973**, *95*, 3262.